Table of Contents

Acknowledgements						
Summary						
Lis	List of Frequently Used Abbreviations List of Tables					
Lis						
List of Figures						
I.	THE	ORETICAL SECTION	1			
1	Intro	duction	1			
	1.1	Moralism impedes appropriate SUD treatment	1			
	1.2	Neuroscience challenges common-sense conceptions of SUD	2			
	1.3	The conceptualization of SUD	5			
	1.4	Dependence or addiction?	8			
2	Brain	-Behavioral Connections in SUD	11			
	2.1	Topics of the thesis	12			
	2.2	Importance of neurocognitive impairment in SUD	13			
	2.3	Substance users' awareness of their neurocognitive status	15			
	2.4	Awareness of neurocognitive impairment in treatment				
		settings	17			
	2.5	Impact of neurocognitive impairment on treatment				
		response and outcome in SUD	21			
	2.6	Assessing neurocognitive functioning and impairment				
		in SUD	25			
	2.7	Implications of neurocognitive impairment for treat-				
		ment providers and recommendations for treatment				
		programs	46			
	2.8	Neurocognitive rehabilitation of patients with SUD	48			
	2.9	Conclusions	51			
3	Opioid Dependence and Maintenance Treatments		53			
	3.1	Opioid dependence: a worldwide burden	53			
	3.2	Opioid maintenance treatments	54			
	3.3	Methadone maintenance treatment	54			
	3.4	Injectable opioid maintenance treatment	57			



	3.5 Injectable heroin prescription in Switzerland: from					
		PROV	E to heroin-assisted treatment	58		
	3.6	Unans	wered questions about injectable heroin prescription	61		
4	Brain	Brain Alterations Associated with Opioid Use Disorders				
	4.1	Genera	al methodological considerations, research limi-			
		tations	and concerns regarding neuropsychological studies	67		
	4.2 Neuropathological findings associated with opioid use		pathological findings associated with opioid use			
		ers	71			
		4.2 .1	Alterations in neurotransmission and cellular			
			functions	72		
		4.2.2	Alterations in brain structure	75		
		4.2.3	Alterations in brain function	78		
		4.2.4	Alterations in functional brain activity and			
			connectivity	80		
	4.3	Neuro	logical complications associated with opioid use	83		
5	Neurocognitive Impairment Associated with Opioid Use Disorders					
	5.1	Recent	t studies on neurocognitive functions in opioid users	89		
	5.2	.2 Motor skills, sensory-perceptual skills and information				
		proces	ssing	94		
		5.2 <u>,</u> 1	Motor dysfunction	95		
		5.2.2	Sensory-perceptual dysfunction	95		
		5.2.3	Motor and information processing skills	96		
		5.2.4	Problems in measuring motor skills and infor-			
			mation processing	98		
	5.3	Visuoj	perceptual, visuospatial and visuoconstructive skills	10 0		
		5.3.1	Visuoperceptual and visuoconstructive skills	100		
		5.3.2	Visuospatial skills	102		
	5.4	Attenti	ion and working memory	103		
		5.4.1	Attention skills	104		
		5.4.2	Working memory skills	105		
		5.4.3	Stimulus-driven perceptual and attentional			
			processing in opioid users	1 07		
	5.5	Memory and learning				
	5.6	Execut	tive functions	114		

		5.6.1 Cognitive flexibility	115	
		5.6.2 Inhibitory control	119	
		5.6.3 Planning and problem solving	122	
		5.6.4 Decision making	124	
	5.7	Speech and language	129	
	5.8	Overall neurocognitive impairment	132	
		5.8.1 Summary of neurocognitive impairs	ment 136	
	5.9	Conclusions and outlook	137	
II.	EMF	PIRICAL SECTION	145	
6	Background			
	6.1	Rapid cortical hemoglobin deoxygenation a	fter heroin	
		and methadone injection in human beings	148	
	6.2	Opioid-associated effects on oxygen saturati	on in hu-	
		man beings	150	
	6.3	Safety of injectable opioid maintenance trea	tment for	
		heroin dependence	151	
	6.4	N-acetylaspartate reduction associated with	long-term	
		IV heroin use	152	
	6.5	Complaints of heroin-maintained patients: a	a survey of	
		symptoms ascribed to diacetylmorphine	154	
	6.6	Symptom complaints of patients prescribed	either oral	
		methadone or injectable heroin	155	
7	A Placebo-Controlled Mixed-Design Study on the Euphoric			
	Effects of Injectable Diacetylmorphine and Methadone		lone 156	
	7.1	Introduction	156	
	7.2	Methods and materials	159	
		7.2.1 Participants	159	
		7.2.2 Experimental design and general pr	ocedures 161	
		7.2.3 Experimental sessions	162	
		7.2.4 Drugs	163	
		7.2.5 Dependent measures	163	
		7.2.6 Toxicology screens and plasma met	hadone	
		concentrations	164	

	7.2.7	Safety procedures and adverse events	164
	7.2.8	Data analysis and statistics	165
7.3	Result	ts	166
	7.3.1	Subjective-effects ratings	166
	7.3.2	Blood oxygen saturation	171
7.4	Discu	ssion and conclusions	174

References

٠